The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
Open accessAbstract
Purpose: To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully human immunoglobulin G 1 monoclonal antibody targeting the vascular endothelial growth factor receptor (VEGFR)-2. Patients and Methods: Patients with advanced solid malignancies were treated once weekly with escalating doses of ramucirumab. Blood was sampled for PK studies throughout treatment. The effects of ramucirumab on circulating vascular endothelial growth factor-A (VEGF-A), soluble VEGFR-1 and VEGFR-2, tumor perfusion, and vascularity using dynamic contrast-enhanced magnetic resonance imaging were assessed. Results: Thirty-seven patients were treated with 2 to 16 mg/kg of ramucirumab. After one patient each developed dose-limiting hypertension and deep venous thrombosis at 16 mg/kg, the next lower dose (13 mg/kg) was considered the MTD. Nausea, vomiting, headache, fatigue, and proteinuria were also noted. Four (15%) of 27 patients with measurable disease had a partial response (PR), and 11 (30%) of 37 patients had either a PR or stable disease lasting at least 6 months. PKs were characterized by dose-dependent elimination and nonlinear exposure consistent with saturable clearance. Mean trough concentrations exceeded biologically relevant target levels throughout treatment at all dose levels. Serum VEGF-A increased 1.5 to 3.5 times above pretreatment values and remained in this range throughout treatment at all dose levels. Tumor perfusion and vascularity decreased in 69% of evaluable patients. Conclusion: Objective antitumor activity and antiangiogenic effects were observed over a wide range of dose levels, suggesting that ramucirumab may have a favorable therapeutic index in treating malignancies amenable to VEGFR-2 inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“Angiogenesis is regulated principally by interactions between vascular endothelial growth factors (VEGFs) and VEGF receptors (VEGFRs) and plays a key role in cancer growth and metastasis.(1-5) VEGF-A is the central regulator of tumor angiogenesis, endothelial proliferation, permeability, and survival.”
BackgroundSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483
Tofts, P. S., Brix, G., Buckley, D. L., Evelhoch, J. L., Henderson, E., Knopp, M. V., Larsson, H. B. W., Lee, T.-Y., Mayr, N. A., Parker, G. J. M., et al. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s · Cited by 3,143
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationThe fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992) · Science · doi:10.1126/science.1312256 · Cited by 2,016
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Molecular and biological properties of vascular endothelial growth factor
Ferrara, N. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900019 · Cited by 1,158
Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., & Sato, M. (1990) · PubMed · Cited by 960
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Prewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 713
Vascular endothelial growth factor and its receptors
Klagsbrun, M., & A. D'Amore, P. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00027-5 · Cited by 682
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E., Thomas, D., Koller, C., Estrov, Z., O'Brien, S., Keating, M., et al. (2000) · Blood · doi:10.1182/blood.v96.6.2240 · Cited by 680
Inoue, M., Hager, J. H., Ferrara, N., Gerber, H.-P., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380
Clark, J. W., Eder, J. P., Ryan, D., Lathia, C., & Lenz, H.-J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2658 · Cited by 342
Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C. G., Schwartz, B., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602584 · Cited by 339
Witte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., & Böhlen, P. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006094117427 · Cited by 307
Moore, M., Hirte, H. W., Siu, L., Oza, A., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C., & Schwartz, B. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi310 · Cited by 305
Holden, S. N., Eckhardt, S. G., Basser, R., de Boer, R., Rischin, D., Green, M., Rosenthal, M. A., Wheeler, C., Barge, A., & Hurwitz, H. I. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi247 · Cited by 304
Self-citationDrevs, J., Siegert, P., Medinger, M., Mross, K., Strecker, R., Zirrgiebel, U., Harder, J., Blum, H., Robertson, J., Jürgensmeier, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2066 · Cited by 303
Adams, V. R., & Leggas, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.022 · Cited by 197
Bruns, C. J., Liu, W., Davis, D. W., Shaheen, R. M., McConkey, D. J., Wilson, M. R., Bucana, C. D., Hicklin, D. J., & Ellis, L. M. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3<488::aid-cncr3>3.0.co;2-x · Cited by 189
Lu, D., Shen, J., Vil, M. D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., & Zhu, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307742200 · Cited by 183
Fracasso, P. M., Burris, H. A., Arquette, M. A., Govindan, R., Gao, F., Wright, L. P., Goodner, S. A., Greco, F. A., Jones, S. F., Willcutt, N. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1542 · Cited by 165
Zhu, Z., Hattori, K., Zhang, H., Jimenez, X., Ludwig, D. L., Dias, S., Kussie, P., Koo, H., Kim, H. J., Lu, D., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402831 · Cited by 158
Britten, C. D., Kabbinavar, F. F., Hecht, J. R., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0498-4 · Cited by 143
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors
Tamura, T., Minami, H., Yamada, Y., Yamamoto, N., Shimoyama, T., Murakami, H., Horiike, A., Fujisaka, Y., Shinkai, T., Tahara, M., et al. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31634-8 · Cited by 139
Lü, D., Jimenez, X., Zhang, H., Böhlen, P., Witte, L., & Zhu, Z. (2001) · International Journal of Cancer · doi:10.1002/ijc.1634 · Cited by 136
Posey, J. A., Ng, T. C., Yang, B., Khazaeli, M. B., Carpenter, M., Fox, F. E., Needle, M., Waksal, H. W., & LoBuglio, A. F. (2003) · PubMed · Cited by 119
Self-citationE2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer
Miller, K. D. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.n.007 · Cited by 118
Zhu, Z., & Witte, L. (1999) · Investigational New Drugs · doi:10.1023/a:1006314501634 · Cited by 93
Dirks, N. L., Nolting, A., Kovar, A., & Meibohm, B. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007313393 · Cited by 84
Ryan, C. J., Stadler, W. M., Roth, B. J., Hutcheon, D., Conry, S., Puchalski, T. A., Morris, C. Q., & Small, E. J. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9050-y · Cited by 71
Zhu, Z., Böhlen, P., & Witte, L. (2002) · Current Cancer Drug Targets · doi:10.2174/1568009023333881 · Cited by 62
Rockwell, P., Neufeld, G., Glassman, A., Caron, D., & Goldstein, N. I. (1994) · Cited by 55
Pharmacokinetics of Monoclonal Antibodies
Kuester, K., & Kloft, C. (2006) · doi:10.1002/9783527609628.ch3 · Cited by 38
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Linifanib, an oral tyrosine kinase inhibitor targeting VEGF and PDGF, and ramucirumab, a monoclonal antibody against VEGFR2 [339] are currently being tested in phase III studies in first-line and second-line indication, respectively.”
BackgroundA global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Metadata
- Authors
- Spratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., Leong, S., O'Bryant, C., Chow, L. Q. M., Serkova, N. J., Meropol, N. J., Lewis, N. L., Chiorean, E. G., Fox, F., Youssoufian, H., Rowinsky, E. K., & Eckhardt, S. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-02-10
- Volume
- 28
- Issue
- 5
- Pages
- 780-787
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153297361
- Cited by
- 549
- References
- 42
- FWCI
- 13.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.